Scandinavian ChemoTech's subsidiary, Vetiqure AB, has today received an order from AniCura Animal Hospital in Jönköping
AniCura Animal Hospital in Jönköping, which during the spring tested and evaluated vetIQure™ for tumour specific electroporation of small animals, sees vetIQure™ as an important complement to its radiation therapy and has today placed an order with the company amounting to 4,000 Euros.
"We have very positive experiences of vetIQure™ and the tumour specific treatments we performed during the spring where the equipment has been an important complement to our radiation therapy," says Nanna Åkerlund Denneberg, Veterinarian and oncology specialist in dogs and cats and user of the company's equipment.
"It is gratifying that we have reached this milestone with AniCura Jönköping, with whom we began a long-term collaboration at the beginning of the year and look forward with excitement to the autumn treatments." - says Anders Johnsson, Chief Operating Officer of Vetiqure AB.
About AniCura
AniCura is one of Europe's leading companies in high-quality veterinary care for pets with clinics in 300 locations across Europe. With a wide range of medical and surgical services, security is created for pet owners through high availability and patient safety. With its 6,000 employees, it takes care of more than 3 million patients every year. AniCura is also a recognized training and referral body. AniCura Group is since 2018 included as a wholly owned subsidiary within Mars Petcare.
For more information see:
https://www.mars.com/made-by-mars/petcare
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: info@penser.se
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Wednesday August 26 2020 at 10.45 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.